JAMA Oncol: Vistusertib in combination with anastrozole for hormone receptor-positive endometrial cancer

Endometrial cancer is often hormone-dependent and can be treated with aromatase inhibito.

Dysregulation of the PI3K-AKT-mTOR pathway has been observed to drive hormone resistance in endometrial cancer, suggesting that mTOR inhibitors can be used in combination with endocrine thera.

This study (VICTORIA) was designed to evaluate the safety and efficacy of the mTOR inhibitor Vistusertib in combination with anastrozole in the treatment of hormone receptor-positive recurrent or metastatic endometrial canc.

This is a multicenter, open-label, randomized clinical trial that enrolled 75 patients with hormone receptor-positive recurrent/metastatic endometrial cancer between April 2016 and October 2019 , randomized 2: 1 Divided into two groups, received Vistusertib (125mg*2 times/day, 2 days/week) and anastrozole (1mg/day, orally) or anastrozole alo.

The primary endpoints were serious adverse events and progression-free rate (8wk-PFR) at weekSecondary endpoints were objective response rate, duration of response, progression-free survival (PFS), overall survival and incidence of adverse even.

Progression-free survival in both groups

Of the 75 patients enrolled, 73 (median age 65 years) received study treatment: 49 in the combination group and 24 in the anastrozole gro.

Week 8 progression-free rates in the combination and anastrozole groups were 63% and 31%, respectively

In conclusion, the results of this study show that the addition of anastrozole to the mTOR inhibitor Vistusertib can improve the progression-free rate, remission rate, prolong progression-free survival , and reduce adverse reactions in patients with hormone receptor-positive recurrent/metastatic endometrial canc.

Original source:

Heudel P, Frenel J, Dalban C, et .